ATE512228T1 - Induzierbare expressionssysteme - Google Patents

Induzierbare expressionssysteme

Info

Publication number
ATE512228T1
ATE512228T1 AT06824268T AT06824268T ATE512228T1 AT E512228 T1 ATE512228 T1 AT E512228T1 AT 06824268 T AT06824268 T AT 06824268T AT 06824268 T AT06824268 T AT 06824268T AT E512228 T1 ATE512228 T1 AT E512228T1
Authority
AT
Austria
Prior art keywords
rtta
inducable
expression systems
nucleic acid
acid molecules
Prior art date
Application number
AT06824268T
Other languages
English (en)
Inventor
Benjamin Berkhout
Atze Taede Das
Original Assignee
Tet Systems Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36013269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE512228(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tet Systems Gmbh & Co Kg filed Critical Tet Systems Gmbh & Co Kg
Application granted granted Critical
Publication of ATE512228T1 publication Critical patent/ATE512228T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT06824268T 2005-11-17 2006-11-17 Induzierbare expressionssysteme ATE512228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077623 2005-11-17
PCT/NL2006/000575 WO2007058527A2 (en) 2005-11-17 2006-11-17 Inducible expression systems

Publications (1)

Publication Number Publication Date
ATE512228T1 true ATE512228T1 (de) 2011-06-15

Family

ID=36013269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824268T ATE512228T1 (de) 2005-11-17 2006-11-17 Induzierbare expressionssysteme

Country Status (10)

Country Link
US (1) US8383364B2 (de)
EP (1) EP1954811B1 (de)
JP (1) JP5155176B2 (de)
AT (1) ATE512228T1 (de)
AU (1) AU2006316288B2 (de)
CA (1) CA2630348C (de)
DK (1) DK1954811T3 (de)
ES (1) ES2366227T3 (de)
NO (1) NO20082783L (de)
WO (1) WO2007058527A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
CA2630348C (en) 2005-11-17 2016-01-12 Stichting Voor De Technische Wetenschappen Inducible expression systems
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2012072814A1 (en) 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2012170436A1 (en) * 2011-06-06 2012-12-13 The Regents Of The University Of California Synthetic biology tools
DK3099709T3 (da) 2014-01-31 2020-02-03 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af stabile antistoffer
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
US20180245038A1 (en) 2015-09-04 2018-08-30 Universita' Degli Studi Di Padova Method for generating somatic stem cells
WO2020069373A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
WO2020069339A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Mutant reverse tetracycline transactivators for expression of genes
CN113584083A (zh) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1989008146A1 (en) 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition of htlv-iii by exogenous oligonucleotides
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
FI951600A7 (fi) 1992-10-05 1995-05-10 Hybridon Inc Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
EP0716570A4 (de) 1993-09-03 1997-12-17 Systemix Inc Genetisch modifizierte menschliche hämatopoietische stammzellen und ihre nachkommen
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
ATE515189T1 (de) * 2001-12-10 2011-07-15 California Inst Of Techn Verfahren zur herstellung von antigenspezifischen lymphozyten
US20050009180A1 (en) * 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
ES2384960T3 (es) 2001-12-18 2012-07-16 Cancer Research Technology Limited Procedimiento para la generación de líneas celulares proliferativas y que se diferencian
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0327384D0 (en) * 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) * 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
US20090217403A1 (en) 2005-06-06 2009-08-27 Hergen Spits Means and methods for generating a t cell against an antigen of interest
CA2630348C (en) 2005-11-17 2016-01-12 Stichting Voor De Technische Wetenschappen Inducible expression systems

Also Published As

Publication number Publication date
AU2006316288B2 (en) 2012-12-20
NO20082783L (no) 2008-08-01
JP2009515550A (ja) 2009-04-16
EP1954811A2 (de) 2008-08-13
US20100040649A1 (en) 2010-02-18
US8383364B2 (en) 2013-02-26
DK1954811T3 (da) 2011-07-04
JP5155176B2 (ja) 2013-02-27
AU2006316288A1 (en) 2007-05-24
WO2007058527A3 (en) 2007-09-20
CA2630348A1 (en) 2007-05-24
ES2366227T3 (es) 2011-10-18
WO2007058527A2 (en) 2007-05-24
CA2630348C (en) 2016-01-12
EP1954811B1 (de) 2011-06-08

Similar Documents

Publication Publication Date Title
NO20082783L (no) Induserbare ekspresjonssystemer
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
EP4105644A3 (de) Systeme und vorrichtungen zur "sequence-by-synthesis"-analyse
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
BRPI0414599A (pt) pirrol-indóis substituìdos
DK2207786T3 (da) 2´-Fluor-2´-deoxytetrahydrouridiner som cytidindeaminasehæmmere
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
DK1836299T4 (da) Polypeptider, der har cellobiohydrolaseaktivitet, og polynukleotider, der koder for disse
WO2009123762A3 (en) Method of screening single cells for the production of biologically active agents
MX2018005512A (es) Agentes de union de esclerostina.
EA200870619A1 (ru) Модифицированный фермент дикамба-монооксигеназа и способы его применения
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
EP2516624A4 (de) Zelllinie 3m
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
WO2007135685A3 (en) Compositions for silencing the expression of gibberellin 2-oxidase and uses thereof
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
CY1112877T1 (el) Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας
EA201000069A1 (ru) Новые гербициды
NO20081470L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse.
ATE532861T1 (de) Expressionsvektor
EA200702193A1 (ru) Гликозилирование белков

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties